City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  92  Clinical trial(s) found  (Page 1 of 4 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 16318 ClinicalTrials.gov Number: NCT02760485

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

COH Protocol Number: 16316

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  Phase 1b/Phase 3 Multicenter Study of Avelumab (MSB0010718c) in Combination Regimens that Include an Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DBCL)

COH Protocol Number: 16305 ClinicalTrials.gov Number: NCT02954796

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  Phase 1 Study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 16273 ClinicalTrials.gov Number: NCT02890368

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase I Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

COH Protocol Number: 16272 ClinicalTrials.gov Number: NCT01822509

Principal Investigator: Alex Herrera, MD
Sponsor: NCI Approved External Peer Review

Title:  A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

COH Protocol Number: 16260 ClinicalTrials.gov Number: NCT02864290

Principal Investigator: Monzr Al malki, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS62P1 Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

COH Protocol Number: 16257 ClinicalTrials.gov Number: NCT02264613

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

COH Protocol Number: 16215 ClinicalTrials.gov Number: NCT02030067

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies

COH Protocol Number: 16203 ClinicalTrials.gov Number: NCT02848248

Principal Investigator: Guido Marcucci, MD
Sponsor: Industrial

Title:  A Phase 1 Study of SGN-CD123A in Patient with Relapsed or Refractory Acute Myeloid Leukemia (AML)

COH Protocol Number: 16180 ClinicalTrials.gov Number: NCT02518113

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients

COH Protocol Number: 16176 ClinicalTrials.gov Number: NCT02448251

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II, Multicenter, Open-label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 16163 ClinicalTrials.gov Number: NCT02268253

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

COH Protocol Number: 16125 ClinicalTrials.gov Number: NCT02743351

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1 Non-Randomized/Phase 2 Randomized Study of ProTmune™ (ex vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Hematologic Malignancies

COH Protocol Number: 16107 ClinicalTrials.gov Number: NCT01307267

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1 Study of PF-05082566 as a Single Agent in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin’s Lymphoma (NHL)

COH Protocol Number: 16102 ClinicalTrials.gov Number: NCT02283775

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1b Study of SAR650984 (Isatuximab) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 16089 ClinicalTrials.gov Number: NCT02549651

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

COH Protocol Number: 16059 ClinicalTrials.gov Number: NCT02684617

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)

COH Protocol Number: 16049 ClinicalTrials.gov Number: NCT02759016

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Phase Ib/II, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

COH Protocol Number: 16047 ClinicalTrials.gov Number: NCT02814669

Principal Investigator: Przemyslaw Twardowski, MD
Sponsor: Industrial

Title:  A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment with an Androgen Pathway Inhibitor

COH Protocol Number: 16036 ClinicalTrials.gov Number: NCT02535338

Principal Investigator: Karen Reckamp, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-80, NCI#9878: A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer

COH Protocol Number: 16034 ClinicalTrials.gov Number: NCT02636036

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase I Multicenter, Open Label Study of Enadenotucirev Combined with PD-1 Inhibitor in Subjects with Metastatic or Advanced Epithelial Tumors

COH Protocol Number: 16006 ClinicalTrials.gov Number: NCT02453087

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase I/IB Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination with Rituximab, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

COH Protocol Number: 15467 ClinicalTrials.gov Number: NCT01953692

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies

COH Protocol Number: 15429 ClinicalTrials.gov Number: NCT02677922

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects with Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

COH Protocol Number: 15428 ClinicalTrials.gov Number: NCT02567656

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.